Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR + Sargramostim in Frontline CLL
NCT00381004Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2006
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate at 6 months and Number of Participants With Overall Response at 6 months. Started Sep 2006; status: completed.
02
Drugs
sargramostim
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00381004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381004.